These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14596633)

  • 1. Pharmacogenetics and public policy: expert views in Europe and North America.
    Melzer D; Detmer D; Zimmern R
    Pharmacogenomics; 2003 Nov; 4(6):689-91. PubMed ID: 14596633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics--legal, ethical and regulatory considerations.
    March R; Cheeseman K; Doherty M
    Pharmacogenomics; 2001 Nov; 2(4):317-27. PubMed ID: 11722282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics: policy needs for personal prescribing.
    Melzer D; Raven A; Ling T; Detmer D; Zimmern R
    J Health Serv Res Policy; 2005 Jan; 10(1):40-4. PubMed ID: 15667703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogenetics and pharmacogenetics: in whose best interests?
    Mackenzie R
    Med Law; 2005 Jun; 24(2):343-54. PubMed ID: 16082870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How molecular medicine transforms policy (and everything else).
    Kean MA; Batchelder KF
    J Biolaw Bus; 2004; 7(3):16-9. PubMed ID: 15460603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethical and public policy challenges for pharmacogenomics.
    Gershon ES; Alliey-Rodriguez N; Grennan K
    Dialogues Clin Neurosci; 2014 Dec; 16(4):567-74. PubMed ID: 25733960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential and limitations of personalized medicine in the doctor-patient relationship.
    Hapgood R
    Pharmacogenomics; 2003 Nov; 4(6):685-7. PubMed ID: 14596632
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetics: a new challenge for health law.
    Roscam Abbing HD
    Med Law; 2007 Dec; 26(4):781-9. PubMed ID: 18284117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized medicine: elusive dream or imminent reality?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance in Europe and North America: divergent approaches.
    Wiktorowicz M; Lexchin J; Moscou K
    Soc Sci Med; 2012 Jul; 75(1):165-70. PubMed ID: 22521677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored medicine: whom will it fit? The ethics of patient and disease stratification.
    Smart A; Martin P; Parker M
    Bioethics; 2004 Aug; 18(4):322-42. PubMed ID: 15449405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuffield Council on Bioethics consultation.
    Lipton P
    Pharmacogenomics; 2003 Jan; 4(1):91-5. PubMed ID: 12517289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["Us" and "them": European and North American attitudes to immigration].
    Livi-bacci M
    Polit Etrang; 1994; 59(3):661-70. PubMed ID: 12346367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
    Prasad K; Breckenridge A
    Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
    Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
    Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.